Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $140.3 million.

  • Apellis Pharmaceuticals' Accumulated Expenses rose 34.83% to $140.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.3 million, marking a year-over-year increase of 34.83%. This contributed to the annual value of $140.2 million for FY2024, which is 968.5% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Accumulated Expenses of $140.3 million as of Q3 2025, which was up 34.83% from $139.0 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Accumulated Expenses' 5-year high stood at $140.3 million during Q3 2025, with a 5-year trough of $69.4 million in Q1 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Accumulated Expenses had a median value of $105.3 million in 2022 and averaged $108.4 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Accumulated Expenses surged by 31295.6% in 2021, and later crashed by 3342.0% in 2022.
  • Apellis Pharmaceuticals' Accumulated Expenses (Quarter) stood at $103.2 million in 2021, then decreased by 7.85% to $95.1 million in 2022, then surged by 34.34% to $127.8 million in 2023, then grew by 9.68% to $140.2 million in 2024, then rose by 0.1% to $140.3 million in 2025.
  • Its Accumulated Expenses was $140.3 million in Q3 2025, compared to $139.0 million in Q2 2025 and $116.1 million in Q1 2025.